Why is the UK subscription model for antibiotics considered successful?
Why is the UK subscription model for antibiotics considered successful?
复制标题
为什么英国的抗生素订阅模式被认为是成功的？
DOI：
10.1016/s2666-5247(23)00250-1
复制
发表时间：
2023
期刊：
影响因子：
--
通讯作者：
Glover RE
中科院分区：
文献类型：
--
作者：
Glover RE
界定成功与否是政策执行的一个关键组成部分，因为公共资金拨付到哪里，公共利益就应该随之而来。有时，出于政治经济原因，或为了应对政策胜利的需要，宣布成功和国际领导地位的愿望可能先于强有力的政策评估。自2023年7月以来，这种围绕成功欲望的话语已经围绕英国的新抗生素订阅计划展开。英国订阅试点旨在应对全球抗生素耐药性危机的加速，其基础是将药品销售量与报销脱钩的概念。为抗生素获取设定固定的支付，而不是将报销与药物销售量挂钩，可以消除过度销售抗生素的动机。1英国试点旨在通过提高商业利润率和鼓励药物抗菌剂研发中迫切需要的创新来克服抗菌剂领域长期缺乏创新的问题。
Defining success is a crucial component of policy delivery, for where public funds are disbursed, public benefit should follow. Sometimes, the desire to proclaim success and international leadership can precede robust policy evaluation, for reasons of political economy, or in response to a need for a policy win. Since July, 2023, such discourse around the desire for success has developed around the UK’s subscription scheme for new antibiotics.Designed in response to the accelerating global crisis of antimicrobial resistance, the UK subscription pilot is based on the concept of delinking the volume of drugs sold from reimbursement. Setting fixed payments for antibiotic access, rather than linking reimbursement to the volume of drugs sold, could eliminate incentives to oversell antimicrobials. 1 The UK pilot purports to overcome the long-standing innovation dearth in the antimicrobial space by increasing commercial profit margins and encouraging urgently needed innovation in pharmaceutical antimicrobial research and development.
影响因子：
2.8
作者：
Glover, Rebecca E.;Petticrew, Mark P.;Thompson, Claire
通讯作者：
Thompson, Claire